We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Investigation of the Presbia Flexivue Microlens™

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02110472
Recruitment Status : Unknown
Verified September 2016 by PresbiBio, LLC.
Recruitment status was:  Active, not recruiting
First Posted : April 10, 2014
Last Update Posted : September 28, 2016
Information provided by (Responsible Party):
PresbiBio, LLC

Brief Summary:
The Presbia Flexivue Microlens is a corneal inlay.

Condition or disease Intervention/treatment Phase
Presbyopia Device: Corneal inlay Phase 3

Detailed Description:

Presbyopia is a multifactorial physiological aging mechanism that leads to a progressive functional loss of near vision. In addition to the use of reading glasses for presbyopia, a wide variety of procedures have been investigated by ophthalmologists to correct this refractive error. Cornea laser surgery with multifocal patterns or monovision approaches were developed including LASIK, PresbyLASIK, photorefractive keratectomy (PRK), laser epithelial keratomileusis (LASEK), thin-flap femto-LASIK or sub-Bowman's keratomileusis (SBK). Conductive keratoplasty (CK), clear lens extraction or cataract surgery using multifocal, pseudo-accommodative intraocular lenses (IOLs) or monovision monofocal IOLs are also some of the techniques that have been used for the treatment of presbyopia.

Corneal laser surgery and CK are minimally invasive methods, but they provoke irreversible changes of the corneal anatomy, whereas scleral surgery and clear lens extraction are more invasive techniques. The necessity to develop a minimally invasive, reversible, and safe surgical technique with an easy learning curve for patients between 45 and 60 years, led to the development of refractive intracorneal lenses (inlays) (such as the AcuFocus, Inc. KAMRA™, ReVision Optics® PresbyLens®, and the Presbia Flexivue Microlens™) placed inside the corneal stroma. These inlays are refractive lenses that have a central zone free of refractive power and a peripheral zone with a standard positive refractive power. These inlays are inserted inside the corneal stroma of the non-dominant eye, generally offering two different focal points, one for the far vision and a different for the near vision respectively. The pocket of the cornea is created using a laser (details to be provided later in this protocol).

The Presbia Flexivue Microlens is intended to improve near vision and decrease dependence on reading glasses in presbyopic adults who are tolerant of monovision (as evaluated by participation in a monovision tolerance trial (5 to 7 days minimum)), who require a reading add of +1.50 D to +3.50 D, who have MRSE between +1.00 D and 0.75 D with no more than 0.75 D of refractive cylinder, and who have stable MRSE within 0.50 D over the past 12 months.

Objective: The primary objective of this study is to evaluate the safety and effectiveness of the Presbia Flexivue Microlens™ (hereinafter referred to as the "Microlens") implanted in presbyopes for improvement of near vision.

Investigational Plan: This is a prospective, non-randomized, unmasked, multicenter clinical investigation. A total of 412 subjects at up to 11 investigational sites in the United States will undergo insertion of the Microlens in non-dominant eyes, and will be followed through 36 months postoperative (assuming an estimated 10% per year lost to follow-up). Each site will contribute a targeted minimum of 20 treated subjects, but no more than 25% of the total subjects treated in the study. Data on a minimum of 300 subjects with 24 month data will be submitted as part of the Premarket Approval; all subjects will be followed through 36 months postoperative. Subjects from outside the United States will not be enrolled in this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 412 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Prospective, Non-randomized, Unmasked, Multicenter Clinical Investigation of the Presbia Flexivue Microlens™ for the Improvement of Near Vision in Emmetropic Presbyopes
Study Start Date : May 2014
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : February 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Presbia Flexivue Microlens Corneal Inlay
Presbia Flexivue Microlens implanted in corneal pocket in nondominant eye
Device: Corneal inlay
Presbia Flexivue Microlens implantation in corneal pocket created in nondominant eyes of emmetropic presbyopes.
Other Names:
  • Presbia Flexivue Microlens
  • Presbia Microlens

Primary Outcome Measures :
  1. Uncorrected near visual acuity - operated eyes [ Time Frame: 24 months postoperative ]
    Uncorrected near visual acuity at 40 cm of 20/40 or better

Secondary Outcome Measures :
  1. Uncorrected near visual acuity - operated eyes [ Time Frame: 24 months postoperative ]
    - Number of lines of improvement uncorrected near visual acuity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects must be emmetropes with presbyopia, between ≥ 45 years and ≤ 60 years of age at time of eligibility visit.
  • Subjects must need a reading add of +1.50 D to +3.50 D.
  • Subjects must have uncorrected near visual acuity of 20/50 or worse.
  • Subjects must have near visual acuity correctable to 20/20 or better in each eye.
  • Subjects must have distance visual acuity correctable to 20/25 or better in each eye.
  • Subjects must have a preoperative spherical equivalent of +1.00 D to -0.75 D with no more than 0.75 D of refractive cylinder as determined by cycloplegic refraction in each eye.
  • Subjects must have a photopic pupil size of > 1.6 mm in the eye to be implanted.

Exclusion Criteria:

  • Subjects in whom the non-dominant eye cannot be determined using one of the methods identified in the test of ocular dominance.
  • Subjects who do not complete the monovision tolerance trial (minimum of 5 to 7 days).
  • Subjects who report that they were not completely satisfied with their vision during the monovision tolerance trial.
  • Subjects who report that they experienced debilitating or significant visual symptoms such as halos, glare, double vision, etc. during the monovision tolerance trial.
  • Subjects with a difference of ≥ 1.00 D between the spherical equivalent manifest refraction and the spherical equivalent cycloplegic refraction.
  • Subject with a preferred near working distance of < 35 cm or > 45 cm.
  • Subjects with corneal thickness < 500 microns in the eye to be implanted.
  • Subjects with clinically significant anterior segment pathology, including cataracts, in either eye.
  • Subjects with residual, recurrent, active ocular or uncontrolled eyelid disease or any progressive corneal abnormalities (including endothelial dystrophy, guttata in the central cornea, etc.) in the eye to be treated.
  • Subjects with keratoconus (or keratoconus suspect), amblyopia, recurrent erosion syndrome or corneal dystrophy in the eye to be treated.
  • Subjects with a history of chronic dry eye not controlled on therapy or with superficial punctuate keratitis (SPK) grade > II (i.e., greater than mild) based on Oxford Grading Scale in the eye to be treated.
  • Subjects with abnormal corneal mires on topography maps of the eye to be treated.
  • Subjects who require canthotomy to generate a corneal tunnel in the eye to be treated.
  • Subjects with progressive retinal pathology with a reasonable chance of causing a reduction in BCVA from preoperative in the eye to be treated.
  • Subjects who have undergone previous intraocular or corneal surgery including cataract and refractive surgery (e.g., LASIK surgery) in either eye.
  • Subjects using ophthalmic medication(s) other than artificial tears for treatment of ocular pathology.
  • Subjects with a history of autoimmune disease, connective tissue disease, or clinically significant atopic syndrome.
  • Subjects with a history of herpes zoster or herpes simplex keratitis.
  • Subjects with a history of steroid-responsive rise in intraocular pressure (IOP), or a preoperative IOP > 21 mmHg or glaucoma.
  • Subjects with distorted, non-reactive, or decentered pupils.
  • Subjects taking medication for the control of diabetes.
  • Subjects on chronic systemic or topical corticosteroids or other immunosuppressive therapy that may affect wound healing, and any immuno-compromised subjects (use of intranasal steroids for seasonal allergies are acceptable).
  • Subjects using systemic medications (e.g., amiodarone) or medications with significant ocular side effects.
  • Subjects who are pregnant, or are considering becoming pregnant during the time of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02110472

Layout table for location information
United States, California
Assil Eye Institute
Beverly Hills, California, United States, 90210
La Jolla, California, United States, 92122
Maloney Vision Institute
Los Angeles, California, United States, 90024
Stanford Eye and Laser Center
Palo Alto, California, United States, 94303
United States, Florida
Center for Sight
Sarasota, Florida, United States, 34239
United States, Illinois
Kraft Eye Institute
Chicago, Illinois, United States, 60602
United States, North Carolina
Physicians Protocol
Greensboro, North Carolina, United States, 27410
United States, Ohio
Cleveland Eye Clinic
Brecksville, Ohio, United States, 44141
United States, Texas
Berkeley Eye and Laser Center
Houston, Texas, United States, 77027
United States, Utah
Hoopes Vision, Laser Correction Center
Draper, Utah, United States, 84020
United States, Virginia
The Eye Center
Fairfax, Virginia, United States, 22031
Sponsors and Collaborators
PresbiBio, LLC
Layout table for investigator information
Study Director: Robert K Maloney, MD, MA Maloney Vision Institute
Study Director: Mickey Gordon, MD Gordon-Weiss-Schanzlin Vision Institute
Additional Information:
Layout table for additonal information
Responsible Party: PresbiBio, LLC
ClinicalTrials.gov Identifier: NCT02110472    
Other Study ID Numbers: CLP-12-001
First Posted: April 10, 2014    Key Record Dates
Last Update Posted: September 28, 2016
Last Verified: September 2016
Keywords provided by PresbiBio, LLC:
Emmetropic presbyopes
Additional relevant MeSH terms:
Layout table for MeSH terms
Refractive Errors
Eye Diseases